News | Heart Failure | July 14, 2017

Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients

JACC report features Vectorious Medical Technologies’ digital wireless sensory implant for measuring pressures in the heart

Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients

July 14, 2017 — A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current and next-generation implantable hemodynamic monitors. The review particularly examines new approaches focused on the direct measurement of left atrial pressure (LAP), seeking to expand the use of pressure-guided congestive heart failure (CHF) management.

The report highlights Vectorious Medical Technologies, an Israeli company developing the world’s first digital wireless sensory implant for measuring LAP (currently available CardioMEMS technology is analog and measures pressure in the pulmonary artery [PAP]). Patients with CHF suffer from repeated admissions to the hospital due to fluid overload, typically presenting with edema of the legs and congestion of the lungs. The conventional approach of monitoring symptoms and measuring daily weights and a “wait and see” attitude, is the basis for the huge unmet need of recurrent hospital admissions, because these methods appear late and are unreliable signs of disease progression. This is also the main driver of the huge cost of this chronic medical condition, more than $30 billion a year, in the United States alone, according to background contained in the review.

“Intracardiac and PAP-guided management has become a focus of hospitalization reduction in CHF,” wrote William T. Abraham, M.D., and Leor Perl, M.D. Abraham is from the Departments of Medicine, Physiology and Cell Biology, Division of Cardiovascular Medicine, and the Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio. Perl is in the Cardiology Department, Rabin Medical Center, Petah Tikva, Israel; on the Sackler Faculty of Medicine, Tel Aviv University; and in the Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, Calif.

LAP, rather than PAP, is a direct reflection of left ventricular filling pressure — which is the primary pressure target for CHF management. Therefore, its direct measurement may provide more clinical information than PAP, according to the authors.

In the JACC review, Abraham and Perl say that CHF outcomes with CardioMEMS PAP technology have been encouraging. They write that, additional, more technologically-advanced, implantable hemodynamic monitoring systems are in development, and newer approaches to the use of this data (such as a physician-directed, patient self-management approach) may yet again revolutionize the management of patients with HF.

Both Abraham and Perl have received consulting fees from Vectorious. Perl is also the medical director.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."

For more information: www.vectoriousmedtech.com

Related Content

Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
VitalConnect Raises $38 Million in Series C Equity Financing
News | Wearable Sensors| November 03, 2017
November 3, 2017 — VitalConnect Inc.
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure| October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart| October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
Abbott SJM St. Jude Confirm RX implantable cardiac monitor (ICM).

The Abbott Confirm RX implantable cardiac monitor (ICM) is smaller than a computer thumb-drive and in implanted in a simple in-office procedure just under the skin.

Technology | Implantable Cardiac Monitor (ICM)| October 23, 2017
October 23, 2017 – The U.S.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Overlay Init